{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:28:52Z","timestamp":1784827732701,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["00088699"],"award-info":[{"award-number":["00088699"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["04-M-0222"],"award-info":[{"award-number":["04-M-0222"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004368","name":"Colgate-Palmolive Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jad.2016.10.026","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T18:18:29Z","timestamp":1477505909000},"page":"560-566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion"],"prefix":"10.1016","volume":"208","author":[{"given":"Steven J.","family":"Pennybaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Niciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Luckenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2016.10.026_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.biopsych.2009.08.038","article-title":"Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression","volume":"67","author":"aan het Rot","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","article-title":"BDNF - a key transducer of antidepressant effects","volume":"102","author":"Bjorkholm","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2016.10.026_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J. Trauma Stress"},{"key":"10.1016\/j.jad.2016.10.026_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1741-7015-9-90","article-title":"Cross-national epidemiology of DSM-IV major depressive episode","volume":"9","author":"Bromet","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.jad.2016.10.026_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.dcn.2015.04.005","article-title":"Impact of family history of alcoholism on glutamine\/glutamate ratio in anterior cingulate cortex in substance-naive adolescents","volume":"16","author":"Cohen-Gilbert","year":"2015","journal-title":"Dev. Cogn. Neurosci."},{"key":"10.1016\/j.jad.2016.10.026_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hup.2475","article-title":"The use of ketamine as an antidepressant: a systematic review and meta-analysis","volume":"30","author":"Coyle","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2015.10.021","article-title":"Neurobiological phenotypes associated with a family history of alcoholism","volume":"158","author":"Cservenka","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.jad.2016.10.026_bib9","first-page":"18","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step dose escalation. Aust N Z","author":"Cusin","year":"2016","journal-title":"J. Psychiatry Feb"},{"key":"10.1016\/j.jad.2016.10.026_bib10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881114527361","article-title":"Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic","volume":"28","author":"Diamond","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4088\/JCP.09m05327blu","article-title":"Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder","volume":"71","author":"DiazGranados","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11920-013-0394-z","article-title":"Ketamine, sleep, and depression: current status and new questions","volume":"15","author":"Duncan","year":"2013","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2016.10.026_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1017\/S1461145712000545","article-title":"Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder","volume":"16","author":"Duncan","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib15","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.biopsych.2012.11.011","article-title":"Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants","volume":"73","author":"Dwyer","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib16","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version, Patient Edition with Psychotic Screen (SCID-I\/P). Biometrics Research","author":"First","year":"2002"},{"key":"10.1016\/j.jad.2016.10.026_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","article-title":"Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression","volume":"17","author":"Haile","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040622315579059","article-title":"Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review","volume":"6","author":"Iadarola","year":"2015","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.jad.2016.10.026_bib19","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/npp.2011.338","article-title":"Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study","volume":"37","author":"Ibrahim","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2016.10.026_bib20","doi-asserted-by":"crossref","first-page":"e932","DOI":"10.4088\/JCP.14m09049","article-title":"Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine","volume":"75","author":"Ionescu","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4088\/JCP.14l09527","article-title":"Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression","volume":"76","author":"Kantrowitz","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.jad.2016.10.026_bib23","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.biopsych.2012.05.031","article-title":"Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients","volume":"72","author":"Laje","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib24","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1038\/tp.2014.105","article-title":"Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression","volume":"4","author":"Lally","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.genhosppsych.2015.01.003","article-title":"Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis","volume":"37","author":"Lee","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bdi.12003","article-title":"Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression","volume":"14","author":"Luckenbaugh","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2016.10.026_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","article-title":"Do the dissociative side effects of ketamine mediate its antidepressant effects?","volume":"159","author":"Luckenbaugh","year":"2014","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2016.10.026_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0034-1377042","article-title":"Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine","volume":"47","author":"Lundin","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib29","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4088\/JCP.08m04659","article-title":"Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"70","author":"Machado-Vieira","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-014-3669-0","article-title":"D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression","volume":"232","author":"Moaddel","year":"2015","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.jad.2016.10.026_bib33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Ketamine and Other NMDA Antagonists: early Clinical Trials and Possible Mechanisms in Depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-pharmtox-011613-135950","article-title":"Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds","volume":"54","author":"Niciu","year":"2014","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"10.1016\/j.jad.2016.10.026_bib36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00702-013-1130-x","article-title":"Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder","volume":"121","author":"Niciu","year":"2014","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jad.2016.10.026_bib37","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.4088\/JCP.13m08698","article-title":"Clinical predictors of ketamine response in treatment-resistant major depression","volume":"75","author":"Niciu","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib38","first-page":"18","article-title":"Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder","author":"Niciu","year":"2014","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib39","first-page":"18","article-title":"Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder","author":"Niciu","year":"2015","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S0033291709006011","article-title":"Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report","volume":"40","author":"Nierenberg","year":"2010","journal-title":"Psychol. Med"},{"key":"10.1016\/j.jad.2016.10.026_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-3223(01)01206-9","article-title":"Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders","volume":"51","author":"Obrocea","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib42","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jad.2014.09.015","article-title":"Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression","volume":"172","author":"Ortiz","year":"2015","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.jad.2016.10.026_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12740\/PP\/21175","article-title":"Factors connected with efficacy of single ketamine infusion in bipolar depression","volume":"48","author":"Permoda-Osip","year":"2014","journal-title":"Psychiatr. Pol."},{"key":"10.1016\/j.jad.2016.10.026_bib44","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1176\/ajp.161.10.1776","article-title":"Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism","volume":"161","author":"Petrakis","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","article-title":"Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"65","author":"Phelps","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0269881113478283","article-title":"Serial infusions of low-dose ketamine for major depression","volume":"27","author":"Rasmussen","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2016.10.026_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40268-015-0081-0","article-title":"Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature","volume":"15","author":"Reinstatler","year":"2015","journal-title":"Drugs R D"},{"key":"10.1016\/j.jad.2016.10.026_bib48","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jad.2016.01.009","article-title":"An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder","volume":"194","author":"Saligan","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2016.10.026_bib50","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archpsyc.65.7.826","article-title":"Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior","volume":"65","author":"Schumann","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/science.2704997","article-title":"Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus","volume":"244","author":"Shors","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jad.2016.10.026_bib52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-979537","article-title":"Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression","volume":"29","author":"Skolnick","year":"1996","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib55","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","article-title":"The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS","volume":"191","author":"Valentine","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2016.10.026_bib56","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2016.10.026_bib57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nn2035","article-title":"Molecular and electrophysiological evidence for net synaptic potentiation in wake and depression in sleep","volume":"11","author":"Vyazovskiy","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jad.2016.10.026_bib58","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","article-title":"Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression","volume":"77","author":"Yang","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib59","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.biopsych.2015.09.006","article-title":"Familial alcoholism risk and the ratio of stimulant to sedative effects of ketamine","volume":"79","author":"Yoon","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2016.10.026_bib60","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271631206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271631206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T00:07:43Z","timestamp":1638662863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503271631206X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":60,"alternative-id":["S016503271631206X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2016.10.026","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2016.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}